J. Goldman & Co’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

J. Goldman & Co’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,155	Closed	-$172K	–	501
2022 Q1	$172K	Hold	2,155	–	–	0.01%	323
2021 Q4	$439K	Buy	+2,155	New	+$538K	0.02%	291
2021 Q3	–	Sell	-5,808	Closed	-$1.51M	–	491
2021 Q2	$1.51M	Buy	5,808 +4,380	+307%	+$1.33M	0.06%	255
2021 Q1	$551K	Sell	1,428 -1,234	-46%	-$498K	0.02%	352
2020 Q4	$1.11M	Sell	2,662 -1,658	-38%	-$522K	0.06%	229
2020 Q3	$1.07M	Buy	+4,320	New	+$878K	0.07%	210

Other funds holding VINC

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

J. Goldman & Co's VINC Position: Q2 2022 in Review

J. Goldman & Co sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2022, closing a stake of 2,155 shares — an estimated $172K sold.

J. Goldman & Co first reported a position in VINC in Q3 2020 and held it in 6 quarters. The position peaked at $1.51M in Q2 2021. 51 funds tracked by Wall St. Rank hold VINC as of Q2 2022.

J. Goldman & Co reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
J. Goldman & Co sold 2,155 Vincerx Pharma, Inc. Common Stock shares in Q2 2022, an estimated $172K.
J. Goldman & Co first reported a position in Vincerx Pharma, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
J. Goldman & Co's Vincerx Pharma, Inc. Common Stock position peaked at $1.51M in Q2 2021.
51 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2022.

Based on J. Goldman & Co's 13F filing for Q2 2022, filed 15 Aug 2022.